Thermo Fisher Scientific Inc. has opened its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, California, which is designed to accelerate the development and commercialization of cell therapies, specifically by supporting biotech, biopharma and translational customers developing cell-based immunotherapies. 

Through this new center, cell therapy developers can leverage Thermo Fisher’s product and technology portfolio and process optimization knowledge to create comprehensive, end-to-end manufacturing workflows that can scale to enable clinical and commercial success.

“Our new Advanced Therapies Collaboration Center represents a significant milestone in our ongoing commitment to deliver solutions that address critical challenges in cell therapy development. By enabling access to our expertise and broad range of instrumentation, reagents, lab equipment and analytical solutions, we aim to help our customers overcome manufacturing hurdles and accelerate their path to commercialization,” said Betty Woo, vice president, cell, gene and advanced therapies, Thermo Fisher Scientific. “By fostering collaboration and innovation, the center is poised to play a pivotal role in helping to advance cell therapies, ultimately improving patient lives.” 

Key ATxCC program benefits include: 

• Access to innovative technologies: Developers gain access to Thermo Fisher laboratory equipment and analytical solutions – even before these technologies are available to the broader market. These advanced technologies can streamline manufacturing, help limit contamination risks and promote product consistency. 
• Protocol and process optimization support: Specialized scientists and engineers facilitate support in creating optimized manufacturing processes and protocols utilizing Thermo Fisher products, helping ensure they are scalable and robust. 
• Ongoing support as therapeutic programs evolve: Dedicated regulatory, quality, and partnership management teams assist developers in growing and advancing their cell therapy programs by addressing new challenges and enabling platform-specific support.